Last10K.com

Melinta Therapeutics, Inc. (MLNT) SEC Filing 8-K Material Event for the period ending Friday, June 28, 2019

Melinta Therapeutics, Inc.

HISTORY TOOLS
CIK: 1838000 Ticker: MLNT

View differences made from one to another to evaluate Melinta Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Melinta Therapeutics, Inc..

Continue

Assess how Melinta Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Melinta Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Melinta Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 10.1: Material Contract
Ticker: MLNT
CIK: 1461993
Form Type: 8-K Corporate News
Accession Number: 0001193125-19-187483
Submitted to the SEC: Mon Jul 01 2019 5:18:56 PM EST
Accepted by the SEC: Mon Jul 01 2019
Period: Friday, June 28, 2019
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. New Agreement
  3. Other Events

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/mlnt/0001193125-19-187483.htm